These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11504169)

  • 1. Hormones, drugs, remodeling and outcome in heart failure and after myocardial infarction.
    Cohn JN
    Cardiovasc Drugs Ther; 2001 Jan; 15(1):9-10. PubMed ID: 11504169
    [No Abstract]   [Full Text] [Related]  

  • 2. Reverse Remodeling and Current Medical Therapy in Heart Failure with Reduced Ejection Fraction.
    Maki H; Takeda N
    Int Heart J; 2020; 61(2):197-198. PubMed ID: 32224600
    [No Abstract]   [Full Text] [Related]  

  • 3. Heart failure after myocardial infarction: clinical implications and treatment.
    Minicucci MF; Azevedo PS; Polegato BF; Paiva SA; Zornoff LA
    Clin Cardiol; 2011 Jul; 34(7):410-4. PubMed ID: 21688276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic administration of an endothelin-A receptor antagonist improves exercise capacity in rats with myocardial infarction-induced congestive heart failure.
    Miyauchi T; Fujimori A; Maeda S; Iemitsu M; Sakai S; Shikama H; Tanabe T; Matsuda M; Goto K; Yamaguchi I
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S64-7. PubMed ID: 15838361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-infarct biomaterials, left ventricular remodeling, and heart failure: is good good enough?
    Zouein FA; Zgheib C; Liechty KW; Booz GW
    Congest Heart Fail; 2012; 18(5):284-90. PubMed ID: 22612796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left ventricular remodeling and heart failure in diabetic patients treated with primary angioplasty for acute myocardial infarction.
    Carrabba N; Valenti R; Parodi G; Santoro GM; Antoniucci D
    Circulation; 2004 Oct; 110(14):1974-9. PubMed ID: 15451792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological intervention for prevention of left ventricular remodeling and improving prognosis in myocardial infarction.
    Ishii H; Amano T; Matsubara T; Murohara T
    Circulation; 2008 Dec; 118(25):2710-8. PubMed ID: 19106394
    [No Abstract]   [Full Text] [Related]  

  • 8. Induced adipocyte cell-sheet ameliorates cardiac dysfunction in a mouse myocardial infarction model: a novel drug delivery system for heart failure.
    Imanishi Y; Miyagawa S; Maeda N; Fukushima S; Kitagawa-Sakakida S; Daimon T; Hirata A; Shimizu T; Okano T; Shimomura I; Sawa Y
    Circulation; 2011 Sep; 124(11 Suppl):S10-7. PubMed ID: 21911798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U; Wollert KC; Drexler H
    Cardiovasc Res; 2009 Feb; 81(3):519-27. PubMed ID: 19019834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
    Fraccarollo D; Galuppo P; Motschenbacher S; Ruetten H; Schäfer A; Bauersachs J
    Basic Res Cardiol; 2014 Jul; 109(4):421. PubMed ID: 24907870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug therapy today: latest thinking on drug therapy post-MI.
    Rodman MJ
    RN; 1981 Jan; 44(1):74-96. PubMed ID: 6905260
    [No Abstract]   [Full Text] [Related]  

  • 12. Cellular events linked to cardiac remodeling in heart failure: targets for pharmacologic intervention.
    Piano MR; Kim SD; Jarvis C
    J Cardiovasc Nurs; 2000 Jul; 14(4):1-23; quiz 119-20. PubMed ID: 10902101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ventricular remodeling and its prevention in the treatment of heart failure.
    Patten RD; Udelson JE; Konstam MA
    Curr Opin Cardiol; 1998 May; 13(3):162-7. PubMed ID: 9649938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction.
    Sanganalmath SK; Barta J; Takeda N; Kumamoto H; Dhalla NS
    Can J Physiol Pharmacol; 2008 Apr; 86(4):180-9. PubMed ID: 18418427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New therapeutic goals--new drugs in heart failure treatment].
    Skóra E; Bilińska ZT
    Kardiol Pol; 2007 Nov; 65(11):1368-75. PubMed ID: 18058588
    [No Abstract]   [Full Text] [Related]  

  • 16. [Drug treatment following an infarction].
    Lasserre B; Périat M
    Rev Med Suisse Romande; 1994 Aug; 114(8):677-81. PubMed ID: 7939090
    [No Abstract]   [Full Text] [Related]  

  • 17. "Fas-ten" your seat belt: anti-apoptotic treatment in heart failure takes off.
    von Harsdorf R
    Circ Res; 2004 Sep; 95(6):554-6. PubMed ID: 15375021
    [No Abstract]   [Full Text] [Related]  

  • 18. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction.
    Fraccarollo D; Widder JD; Galuppo P; Thum T; Tsikas D; Hoffmann M; Ruetten H; Ertl G; Bauersachs J
    Circulation; 2008 Aug; 118(8):818-27. PubMed ID: 18678774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ramipril attenuates left ventricular remodeling by regulating the expression of activin A-follistatin in a rat model of heart failure.
    Wei Q; Liu H; Liu M; Yang C; Yang J; Liu Z; Yang P
    Sci Rep; 2016 Sep; 6():33677. PubMed ID: 27642098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carperitide and adiponectin--how are they connected each other to benefit acute decompensated heart failure?
    Asanuma H; Kitakaze M
    Circ J; 2009 Dec; 73(12):2206-7. PubMed ID: 19940369
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.